It's #GivingTuesday!

Donate to Myeloma Research Today

It's Giving Tuesday! This year, we are donating 100% of Giving Tuesday proceeds to three cutting-edge myeloma research projects from our Myeloma Crowd Research Initiative (MCRI). Each project was carefully selected by our team and we believe each will have a lasting impact on myeloma research.

Thank you to all those that have donated! As of this morning, we have raised over $65,000 for myeloma research. We are blown away and inspired by your generosity - thank you, thank you! Every donation, whether great or small, makes an incredible difference.

Know that your stories, kindness, generosity and support for every one of our programs and initiatives means so much to our team. Your donation is funding a better myeloma tomorrow for you!

With the link below, you can donate or share and encourage those you love to support this research. We need your help because we "Can't Wait for a Cure!" 

MCRI RESEARCH PROJECTS

David Chung, MD, PhD

Memorial Sloan Kettering Cancer Center

Creating an Immune System Signature

Why do some multiple myeloma patients relapse early after stem cell transplant while others stay in remission for many years? The patient’s immune system may be a key factor.  Dr. Chung’s research will review patients who have undergone stem cell transplant. He will study three different parts of their immune system after transplant – T cells, lymphocytes and myeloid derived suppressor cells (MDSCs) and will compare patients with early vs. late relapse. He will then combine that immune system signature with the myeloma genetics of each patient to understand the impact they have together. 

Cesar Rodriguez, MD

Wake Forest University

Testing Your Individual Myeloma Tumor Against Available Myeloma Therapies

Each myeloma patient's tumor is unique and can change over time. Dr. Rodriguez is using a new 3D organoid tumor modeling platform which allows the testing of over 50 myeloma treatment combinations against your specific tumor (including your bone marrow microenvironment) to identify which treatments will work best for your type of myeloma. This personalized approach will help you find useful drug combinations that will have the most impact and avoid treatments that will be ineffective.

Fenghuang (Frank) Zhan, PhD

University of Iowa

Targeting CD24 to Eliminate Myeloma Stem Cells

Myeloma stem cells (or early progenitor cells before they become plasma cells) may not be killed with current myeloma therapies and could be the cause of relapse. Dr. Zhan has identified the presence of CD24 as a strong candidate as a cancer stem cell marker and believes that high CD24 levels lead to more aggressive myeloma and earlier death. His work will test patient samples for the presence of CD24 and assess outcomes while also identifying CD24 monoclonal antibodies that could impact this target. 

Donate to Myeloma Research Today